All In MedTech

Device Trial Radar · NCT00630916

Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve

Last checked: Nov 19, 2026Latest source record: Sep 22, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

756

Actual

Start

Nov 2003

Primary completion

Dec 2005

Study completion Dec 2007

Sponsor

Lead sponsor
Sorin Group USA, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 7, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a trial to demonstrate the safety and effectiveness of the Mitroflow Aortic Heart Valve when used to replace a diseased or dysfunctional aortic valve or aortic valve prosthesis.

Conditions

  • Heart Valve Diseases

Interventions

  • Mitroflow Aortic Heart ValveDevice

    Replacement of the native aortic valve or a previously implanted prosthetic aortic valve

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Adverse Events and Mortality for the Mitroflow Aortic Heart Valve RepairTime frame: Late postoperative
  2. Mean GradientTime frame: 12 months
  3. Effective Orifice AreaTime frame: 12 months

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner Good Samaritan

    Phoenix, Arizona

  • The University of Arizona

    Tucson, Arizona

  • Sharp Memorial Hospital

    San Diego, California

23 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.